Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim C Ohaegbulam

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Chest|June 20, 2020
Being Here Now: Perspectives of Preliminary Medicine Residents at the Epicenter of the COVID-19 PandemicAdam M Karp, Kim C Ohaegbulam
International Journal of Radiation Oncology, Biology, Physics|April 15, 2022
Back to the ORKim C Ohaegbulam, Ravi A Chandra
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2016
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer ImmunotherapyElodie Picarda, Kim C Ohaegbulam, Xingxing Zang
Journal of Medical Radiation Sciences|September 16, 2023
From planned neck dissection to PET response to circulating tumour DNA: changes in post-treatment assessment of HPV-driven oropharyngeal cancer<sup>†</sup>Carl M Post, Kim C Ohaegbulam, Timur Mitin
Oncoimmunology|September 28, 2013
B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two citiesHyungjun Jeon, Kim C Ohaegbulam, Yael M Abadi, et al.
American Journal of Therapeutics|August 18, 2020
Vitamin D Supplementation in COVID-19 Patients: A Clinical Case SeriesKim C Ohaegbulam, Mohamed Swalih, Pranavkumar Patel, et al.
Trends in Molecular Medicine|December 3, 2014
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathwayKim C Ohaegbulam, Amer Assal, Eszter Lazar-Molnar, et al.
Oncotarget|November 16, 2017
Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cellsKim C Ohaegbulam, Weifeng Liu, Hyungjun Jeon, et al.
The American Journal of Managed Care|February 4, 2026
Real-world insights on biomarker testing patterns and implications for mNSCLC therapy selectionAmy Stanford, Shawn Boykin, Karishma Desai, et al.
Nature Communications|May 6, 2022
The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapyPeter John, Marc C Pulanco, Phillip M Galbo, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Chest|June 20, 2020
Being Here Now: Perspectives of Preliminary Medicine Residents at the Epicenter of the COVID-19 PandemicAdam M Karp, Kim C Ohaegbulam
International Journal of Radiation Oncology, Biology, Physics|April 15, 2022
Back to the ORKim C Ohaegbulam, Ravi A Chandra
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2016
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer ImmunotherapyElodie Picarda, Kim C Ohaegbulam, Xingxing Zang
Journal of Medical Radiation Sciences|September 16, 2023
From planned neck dissection to PET response to circulating tumour DNA: changes in post-treatment assessment of HPV-driven oropharyngeal cancer<sup>†</sup>Carl M Post, Kim C Ohaegbulam, Timur Mitin
Oncoimmunology|September 28, 2013
B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two citiesHyungjun Jeon, Kim C Ohaegbulam, Yael M Abadi, et al.
American Journal of Therapeutics|August 18, 2020
Vitamin D Supplementation in COVID-19 Patients: A Clinical Case SeriesKim C Ohaegbulam, Mohamed Swalih, Pranavkumar Patel, et al.
Trends in Molecular Medicine|December 3, 2014
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathwayKim C Ohaegbulam, Amer Assal, Eszter Lazar-Molnar, et al.
Oncotarget|November 16, 2017
Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cellsKim C Ohaegbulam, Weifeng Liu, Hyungjun Jeon, et al.
The American Journal of Managed Care|February 4, 2026
Real-world insights on biomarker testing patterns and implications for mNSCLC therapy selectionAmy Stanford, Shawn Boykin, Karishma Desai, et al.
Nature Communications|May 6, 2022
The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapyPeter John, Marc C Pulanco, Phillip M Galbo, et al.
Pageof 2